These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19048117)

  • 1. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
    Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
    Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
    Corroyer-Dulmont A; Pérès EA; Petit E; Guillamo JS; Varoqueaux N; Roussel S; Toutain J; Divoux D; MacKenzie ET; Delamare J; Ibazizène M; Lecocq M; Jacobs AH; Barré L; Bernaudin M; Valable S
    Neuro Oncol; 2013 Jan; 15(1):41-56. PubMed ID: 23115160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
    Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
    Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
    Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
    J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
    Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
    Lefranc F; James S; Camby I; Gaussin JF; Darro F; Brotchi J; Gabius J; Kiss R
    J Neurosurg; 2005 Apr; 102(4):706-14. PubMed ID: 15871514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avastin: more questions than answers. .
    Desjardins A; Sampson JH
    J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
    Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
    Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
    Reardon DA; Desjardins A; Peters K; Gururangan S; Sampson J; Rich JN; McLendon R; Herndon JE; Marcello J; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
    J Neurooncol; 2011 Jun; 103(2):371-9. PubMed ID: 20853132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current evidence of temozolomide and bevacizumab in treatment of gliomas.
    Nanegrungsunk D; Onchan W; Chattipakorn N; Chattipakorn SC
    Neurol Res; 2015 Feb; 37(2):167-83. PubMed ID: 25033940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.
    Ramezani S; Vousooghi N; Ramezani Kapourchali F; Yousefzadeh-Chabok S; Reihanian Z; Alizadeh AM; Khodayari S; Khodayari H
    Life Sci; 2019 Dec; 239():116880. PubMed ID: 31678282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
    Goldwirt L; Beccaria K; Carpentier A; Idbaih A; Schmitt C; Levasseur C; Labussiere M; Milane A; Farinotti R; Fernandez C
    J Neurooncol; 2015 Apr; 122(2):273-81. PubMed ID: 25794638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
    Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
    J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
    Garros-Regulez L; Aldaz P; Arrizabalaga O; Moncho-Amor V; Carrasco-Garcia E; Manterola L; Moreno-Cugnon L; Barrena C; Villanua J; Ruiz I; Pollard S; Lovell-Badge R; Sampron N; Garcia I; Matheu A
    Expert Opin Ther Targets; 2016; 20(4):393-405. PubMed ID: 26878385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
    Jones-Bolin S; Zhao H; Hunter K; Klein-Szanto A; Ruggeri B
    Mol Cancer Ther; 2006 Jul; 5(7):1744-53. PubMed ID: 16891460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.